Overview

Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions

Status:
Completed

Trial end date:
2011-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the response rate of cetuximab plus irinotecan every 2 weeks in patients harboring wild-type KRAS with and without detectable EGFR-expressing metastatic CRC after failure to irinotecan in an exploratory manner.

Phase:

Phase 2

Details

Lead Sponsor:

Asan Medical Center

Treatments:

Camptothecin
Cetuximab
Irinotecan